BTK News

News

Ibrutinib Maintenance Demonstrates Feasibility Post-Induction Therapy Among Patients With Previously Treated MCL

11/28/2023

Jordan Kadish

BTK inhibitor ibrutinib maintenance following induction chemo-immunotherapy was feasible and demonstrated manageable safety among certain patients with treatment-naive mantle cell lymphoma.

BTK inhibitor ibrutinib...

11/28/2023

Oncology

News

Obinutuzumab, Ibrutinib, and Venetoclax Combination Demonstrates Sustained Remissions Among Patients With High-Risk CLL

11/03/2023

Jordan Kadish

A regimen consisting of obinutuzumab, ibrutinib, and venetoclax demonstrated promising sustained remission among patients with high-risk chronic lymphocytic leukemia with del(17p) and/or TP53 mutation, according to a final analysis of the...

A regimen consisting of...

11/03/2023

Oncology

News

BTK Inhibitor Zanubrutinib vs Ibrutinib Among Patients With Waldenström Macroglobulinemia

09/27/2023

Jordan Kadish

BTK inhibitor zanubrutinib exhibited similar efficacy and improved safety compared to ibrutinib among patients with Waldenström macroglobulinemia, according to a final analysis of the phase 3 ASPEN trial.

BTK inhibitor zanubrutinib...

09/27/2023

Oncology

News

Ibrutinib Plus Rituximab Demonstrates Efficacy as Second-Line Treatment for Patients With CLL and R/R AIHA/PRCA

09/21/2023

Jordan Kadish

A phase 2 trial found that ibrutinib plus rituximab demonstrated efficacy among patients with CLL and steroid refractory autoimmune cytopenias such as autoimmune hemolytic anemia and pure red cell aplasia.

A phase 2 trial found that...

09/21/2023

Oncology

News

BTK Inhibitor Ibrutinib Plus Venetoclax Improved PFS vs Chlorambucil and Obinutuzumab Regimen Among Older Patients With Previously Untreated CLL

09/01/2023

Jordan Kadish

BTK inhibitor ibrutinib plus BCL-2 inhibitor venetoclax improved progression-free survival among older or comorbid patients with previously untreated chronic lymphocytic leukemia vs treatment with chlorambucil and obinutuzumab.

BTK inhibitor ibrutinib plus...

09/01/2023

Oncology

News

Patients With BCL2/MYC High-Expressing Non-GCB DLBCL May Be Preferentially Responsive to BTK Inhibitor Ibrutinib Plus R-CHOP Regimen

08/02/2023

Jordan Kadish

Patients with high BCL2/MYC coexpression non-GCB DLBCL may demonstrate improved event-free survival from the addition of BTK inhibitor ibrutinib to R-CHOP treatment, according to an analysis of the phase 3 PHOENIX trial.

Patients with high BCL2/MYC...

08/02/2023

Oncology

News

Nivolumab Plus BTK Inhibitor Ibrutinib Demonstrates Activity, Safety Among Patients With DLBCL Richter Transformation

07/17/2023

Jordan Kadish

According to a phase 2 trial, the combination of nivolumab and BTK inhibitor ibrutinib is an active and safe regimen among patients with diffuse large B-cell lymphoma Richter transformation.

According to a phase 2 trial,...

07/17/2023

Oncology

News

Clinical Outcomes After BTK Inhibitor and B-Cell Lymphoma 2 Inhibitor Treatment Among Patients With CLL

06/08/2023

Jordan Kadish

The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...

The real-world response rates...

06/08/2023

Oncology

News

BTK Inhibitor Acalabrutinib With or Without Obinutuzumab Demonstrated Improved Quality-Adjusted Survival Time Among Patients With Treatment-Naive CLL

06/06/2023

Jordan Kadish

A phase 3 trial indicated that acalabrutinib with or without obinutuzumab resulted in improved quality-adjusted time without symptoms and toxicity vs chlorambucil plus obinutuzumab for patients with previously untreated CLL.

A phase 3 trial indicated that...

06/06/2023

Oncology

News

Ibrutinib Demonstrated Efficacy Among Patients With Heavily Pretreated R/R MCL

05/01/2023

Jordan Kadish

Findings from a multicenter real-world retrospective analysis indicate that BTK inhibitor ibrutinib demonstrated good efficacy among patients with heavily pretreated R/R mantle cell lymphoma.

Findings from a multicenter...

05/01/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology